Randomized Trial Will Test Whether Nasogastric Tubes Are Necessary in Adhesive Small Bowel Obstruction
Adhesive small bowel obstruction remains one of the most familiar and frustrating surgical emergencies, and nasogastric tubes have long been treated as a default part of its early management. This protocol now sets up a direct test of that habit. Investigators plan a single-center, prospective, non-inferiority randomized controlled trial to determine whether patients with ASBO can be managed safely without an NGT while avoiding worse operative outcomes.
The rationale is straightforward and clinically uncomfortable. NGT insertion can be painful, poorly tolerated, and associated with complications, yet it persists as standard practice despite a lack of prospective trial evidence proving benefit in this setting. Observational work has raised the possibility that patients managed with NGTs may actually have poorer outcomes and a higher rate of operative intervention than those treated without one. Those signals do not establish causality, but they are strong enough to justify a controlled study rather than another decade of routine use by assumption.
One sentence captures the stakes: the tube may be common, but the evidence base for mandatory use is not.
Operative Intervention at Day 30 as the Primary Test of Non-Inferiority
The primary endpoint is the rate of operative intervention, assessed through medical record review at day 30 after discharge. That endpoint is clinically meaningful because the central question is not whether the tube can decompress the stomach in the short term, but whether omitting it changes the downstream need for surgery. In ASBO, small shifts in the threshold for operation, recognition of failure of nonoperative management, or progression to ischemia can alter the entire hospital course.
Investigators chose a non-inferiority framework rather than a superiority design, which fits the clinical question. The aim is not to prove that no-NGT management is better in every sense, but to show that it is not unacceptably worse than standard care on the outcome that most directly affects surgical decision-making. The trial is powered at 80% to detect a clinically relevant difference of 10% between groups, and the target sample size is 490 participants. That design gives the study enough statistical structure to judge whether a less invasive approach can stand beside routine decompression without crossing a clinically important boundary.
What Else the Protocol Will Measure Beyond the Tube Decision
The secondary outcomes go well beyond the operating room. Investigators will track bowel resection or bowel ischaemia, length of hospital stay, length of ICU stay, time to operative intervention, ICU admission, postoperative complications classified by Clavien-Dindo, pulmonary complications measured with the Melbourne Group Scale, 90-day mortality, NGT-specific complications, Gastrografin use, and quality of life using the EQ-5D-5L at admission, day 30, and day 90.
That list reveals how much of ASBO care remains tied to trade-offs rather than certainty. A patient may avoid surgery initially but spend more time in hospital, require ICU support, or develop respiratory complications related to aspiration or operative rescue. Another may tolerate conservative treatment well but experience pain, distress, or device-related harm from the tube itself. By capturing both procedural and patient-centered outcomes, the trial is positioned to measure whether a simplified approach changes not just the surgical endpoint but the lived burden of treatment.
The study will also examine the rate of pulmonary complications, an especially relevant measure when considering NGT use in a population often managed under close medical observation. Tube insertion itself is not biologically neutral. It can provoke discomfort, interfere with swallowing, and create its own complication profile, while its intended physiologic benefit is decompression of proximal bowel and stomach to reduce vomiting and aspiration risk. If no-NGT management performs similarly on respiratory outcomes and operative intervention, the case for routine tube placement weakens substantially.
Why the Trial Design Matters in Routine Surgical Care
ASBO is usually caused by intra-abdominal adhesions that mechanically obstruct the bowel, producing distension, vomiting, pain, and dehydration. In that setting, decompression has long been used as a bridge to resolution or to surgery. Yet long-standing practice can persist in the absence of randomized evidence, especially when the intervention is simple, inexpensive, and embedded in surgical culture. This protocol addresses that gap directly.
The trial is being conducted at a single center, which may limit generalizability, but it also allows a tightly controlled assessment of protocol adherence and outcome ascertainment. Randomization between NGT and no NGT should help isolate the effect of the tube itself from the severity of obstruction, clinician preference, and local practice variation. Intention-to-treat analysis will preserve the benefit of that random assignment and reflect real-world decision pathways, where treatment changes can occur after enrollment.
The choice to review operative intervention at 30 days after discharge is also sensible in a condition where the immediate inpatient course does not always tell the whole story. Some patients improve initially and return later with recurrent obstruction or delayed surgery. A post-discharge window broadens the lens beyond a single admission and captures a more complete clinical trajectory.
Ethics Approval, Registration, and the Evidence Gap Ahead
Ethics approval has already been granted by the Hunter New England Human Research Ethics Committee, and the study is prospectively registered with the Australia and New Zealand Clinical Trials Registry under ACTRN12623000341628. Those details matter because they indicate that the question will be answered prospectively rather than reconstructed from retrospective chart review after the fact.
No results are available yet, so the protocol cannot settle whether routine NGT use should remain a default in ASBO. What it does establish is a credible plan to test a widely used intervention against a clinically relevant comparator with hard outcomes, patient-reported quality of life, and safety endpoints. If the no-NGT arm proves non-inferior for operative intervention and does not worsen complications, the implications will reach beyond a single tube choice. They will challenge a deep-seated assumption in obstructive surgery and push practice toward a more selective approach based on evidence rather than inertia.